Diligence memo · auto-generated · as of July 2, 2026

Cardax Pharma, Inc.

Cardax Pharma, Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Cardax Pharma, Inc. operates in Pharmaceuticals, based in HONOLULU.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Cardax Pharma, Inc. has raised $2.9M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $2.1M on 2014-01-03.

Most recent recorded round closed around 2014-01-03.

Valuation (modeled)modeled

Provath models Cardax Pharma, Inc. at approximately $79M (range $1.6M–$620M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.19× the median modeled value of Seed Pharmaceuticals companies in 2013–2015 (51 peers) — value vs value, same stage and era. Within the normal band (119% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 7 months.

Last raise 12.5 yr ago; this sector typically re-raises about every 13 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 2.7× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 33% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 51% of those peers.

Closest niche peers: Assured Pharma, Inc., Wellesley Pharmaceuticals Llc, Generico, Llc, Aggamin Pharmaceuticals, LLC, Abeona Therapeutics LLC.

Peoplefiled

3 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.